Expert Interview
A Second Look: Discussion of Artiva Biotherapeutics Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 for B-NHL
Ticker(s): ARTV, Artiva BiotherapeuticsInstitution: Rutgers University
- Assistant professor at Rutgers University and medical hematologist oncologist.
- Currently manages 35 patients for Sickle cell disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
